Childhood Mortality in a Cohort Treated With Mass Azithromycin for Trachoma | Zendy

Jeremy D. Keenan | Zendy; Berhan Ayele | Zendy; Teshome Gebre | Zendy; M. Zerihun | Zendy; Zhaoxia Zhou | Zendy; Jenafir House | Zendy; Bruce D. Gaynor | Zendy; Travis C. Porco | Zendy; Paul M. Emerson | Zendy; Thomas M. Lietman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Childhood Mortality in a Cohort Treated With Mass Azithromycin for Trachoma

Author(s) -

Jeremy D. Keenan,

Berhan Ayele,

Teshome Gebre,

M. Zerihun,

Zhaoxia Zhou,

Jenafir House,

Bruce D. Gaynor,

Travis C. Porco,

Paul M. Emerson,

Thomas M. Lietman

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir069

Subject(s) - azithromycin , trachoma , medicine , cohort , chlamydia , diarrhea , malaria , cohort study , chlamydia trachomatis , pediatrics , immunology , antibiotics , pathology , microbiology and biotechnology , biology

Mass azithromycin distributions are used to clear ocular strains of chlamydia that cause trachoma, but treatments may also affect respiratory infections, diarrhea, and malaria. Here, we monitor a large cohort in which almost 90% of individuals received azithromycin. We assess whether receiving treatment is associated with reduced all-cause and infectious childhood mortality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research